<DOC>
	<DOCNO>NCT01514825</DOCNO>
	<brief_summary>The purpose study evaluate safety plasma concentration change YM150 repeat administration healthy elderly male female subject .</brief_summary>
	<brief_title>A Study Investigate Plasma Concentration YM150 After Repeated Administration Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Darexaban</mesh_term>
	<criteria>Healthy , judge investigator subinvestigator base result physical examination test Body weight : male : ≥45.0 kg , &lt; 85.0 kg ; female : ≥40.0 kg , &lt; 75.0 kg BMI ( screen ) : ≥17.6 , &lt; 30.0 Use investigational drug another clinical study postmarketing clinical study within 120 day administration study drug Donated 400 mL whole blood within 90 day , 200 mL whole blood within 30 day , blood component within 14 day screen assessment . Any surgical intervention ( include tooth extraction ) trauma within 90 day hospitalization administration , plan surgical intervention within 10 week final administration A deviation normal reference range blood pressure , pulse rate , body temperature , 12lead ECG PT aPTT blood coagulation test outside upper low reference limit ( PT : 9.9 15.4 sec . ; aPTT : 22.5 49.5 sec . ) Upper gastrointestinal disease ( e.g . nausea , vomit , stomachache ) within 7 day study Concurrent previous hepatic disease ( e.g . viral hepatitis , druginduced liver injury ) Concurrent previous heart disease ( e.g . congestive heart failure , angina pectoris , arrhythmia require treatment ) Concurrent previous respiratory disease ( e.g . serious bronchial asthma , chronic bronchitis ; except history childhood asthma ) Concurrent previous renal disease ( e.g . acute renal failure , glomerulonephritis , interstitial nephritis ; except history calculus ) Concurrent previous malignant tumor Excessive smoking drinking habit [ measure `` excessive '' : alcohol : average 45 g/day ( 633 mL bottle beer contain 25 g alcohol , 180 mL Japanese sake contain 22 g alcohol ) , smoke : average 20 cigarettes/day ] Previous treatment YM150</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>YM150</keyword>
	<keyword>Plasma concentration</keyword>
	<keyword>darexaban</keyword>
	<keyword>Healthy elderly subject</keyword>
	<keyword>Pharmacokinetics YM150</keyword>
</DOC>